Posts by tag
acalabrutinib
1 post
Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib plus the BCL2 inhibitor venetoclax (with or without the CD20 inhibitor obinutuzumab), delivered as fixed-duration therapies, significantly improved progression free survival in comparison with standard-of-care chemotherapy in previously untreated patients…